β2受体激动剂能够提高气道平滑肌细胞内cAMP水平，通过松弛气道平滑肌实现气管舒张的作用，已成为目前主要的慢性阻塞性肺疾病（COPD）治疗药物。奥达特罗是由勃林格殷格翰公司研发的用于治疗COPD及哮喘的新分子实体。根据临床研究的报道，作为一种每日给药一次的新一代长效β2受体激动剂（LABA），其疗效可维持24 h，使用方便且能够提高患者的依从性，在一系列临床试验中表现出了良好的应用前景。

β2-Adrenoceptor agonists could increase the level of cAMP in airway smooth muscle cells and be used for the treatment of chronic obstructive pulmonary disease (COPD) due to their bronchodilatory effect. Olodaterol is a new molecular entity developed by Boehringer Ingelheim for the treatment of COPD and asthma. Published data of clinical research show that olodaterol is a promising once-daily long-acting β2-adrenoceptor agonist (LABA) and the curative effect could last over 24 h. LABA offers an improved convenience and better compliance for the patient.